Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Press brief by Jeffrey Jones, MD, MPH of the The Ohio State University, Columbus, OH, on a cross-study analysis of treatment outcomes of 243 patients with 17p del CLL treated with ibrutinib at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.